Profile data is unavailable for this security.
About the company
SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.
- Revenue in USD (TTM)140.14m
- Net income in USD67.04m
- Incorporated1999
- Employees29.00
- LocationSCYNEXIS Inc1 Evertrust Plaza, 13Th FloorJERSEY CITY 07302-6548United StatesUSA
- Phone+1 (201) 884-5485
- Fax+1 (919) 544-8697
- Websitehttps://www.scynexis.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aileron Therapeutics Inc | 0.00 | -15.73m | 63.82m | 15.00 | -- | 2.67 | -- | -- | -3.39 | -3.39 | 0.00 | 20.12 | 0.00 | -- | -- | 0.00 | -24.58 | -65.99 | -26.17 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
| Aeon Biopharma Inc | 0.00 | -36.63m | 64.24m | 10.00 | -- | -- | -- | -- | -0.9859 | -0.9859 | 0.00 | -4.12 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.0045 | -- | -- | -- | -- | 30.30 | -- | -- | -- |
| Medicinova Inc | 1.00m | -8.57m | 64.25m | 13.00 | -- | 1.03 | -- | 64.25 | -0.1748 | -0.1748 | 0.0204 | 1.27 | 0.0142 | -- | -- | 76,923.08 | -12.21 | -15.36 | -12.80 | -15.90 | -- | -- | -857.15 | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
| Mural Oncology PLC | 0.00 | -207.45m | 64.81m | 117.00 | -- | 0.2423 | -- | -- | -12.43 | -12.43 | 0.00 | 15.81 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
| Bioqual Inc | 62.86m | 957.02k | 64.85m | 108.00 | 67.76 | 1.67 | 18.49 | 1.03 | 1.07 | 1.07 | 70.28 | 43.41 | 1.04 | -- | 2.99 | -- | 1.59 | 8.14 | 1.80 | 9.52 | 14.13 | 19.36 | 1.52 | 7.13 | -- | -- | 0.00 | 21.43 | -5.27 | 11.79 | -84.12 | -25.26 | 1.60 | 10.76 |
| Lantern Pharma Inc | 0.00 | -15.96m | 66.06m | 21.00 | -- | 1.61 | -- | -- | -1.47 | -1.47 | 0.00 | 3.82 | 0.00 | -- | -- | 0.00 | -31.15 | -28.83 | -32.91 | -30.17 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.93 | -- | -- | -- |
| SCYNEXIS Inc | 140.14m | 67.04m | 66.87m | 29.00 | 1.37 | 0.9026 | -- | 0.4772 | 1.29 | 1.29 | 2.90 | 1.96 | 1.30 | 34.76 | 133.41 | 4,832,483.00 | 62.01 | -30.02 | 73.55 | -36.35 | 88.85 | -- | 47.84 | -86.76 | 6.26 | 33.49 | 0.1428 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
| enVVeno Medical Corp | 0.00 | -23.52m | 67.25m | 31.00 | -- | 1.46 | -- | -- | -1.96 | -1.96 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -52.09 | -58.43 | -53.82 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
| Carisma Therapeutics Inc | 10.63m | -73.50m | 67.30m | 17.00 | -- | 1.41 | -- | 6.33 | -3.70 | -3.70 | 0.411 | 1.15 | 0.0694 | -- | -- | 625,294.10 | -47.96 | -25.47 | -56.78 | -27.87 | -- | -- | -691.39 | -236.32 | -- | -- | 0.0211 | -- | 50.69 | 148.16 | -5,817.86 | -- | -- | -- |
| Maia Biotechnology Inc | 0.00 | -19.77m | 68.58m | 13.00 | -- | 116.68 | -- | -- | -1.49 | -1.49 | 0.00 | 0.0281 | 0.00 | -- | -- | 0.00 | -201.88 | -- | -347.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.91 | -- | -- | -- |
| Rallybio Corp | 0.00 | -74.56m | 69.20m | 43.00 | -- | 0.652 | -- | -- | -1.84 | -1.84 | 0.00 | 2.81 | 0.00 | -- | -- | 0.00 | -50.37 | -- | -54.02 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.87 | -- | -- | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -7.45m | 69.36m | 12.00 | -- | 4.06 | -- | -- | -0.5863 | -0.5863 | 0.00 | 1.31 | 0.00 | -- | -- | 0.00 | -82.73 | -- | -113.11 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.15 | -- | -- | -- |
| Landos Biopharma Inc | 0.00 | -21.94m | 69.50m | 19.00 | -- | 2.18 | -- | -- | -3.49 | -3.49 | 0.00 | 10.20 | 0.00 | -- | -- | 0.00 | -52.67 | -59.84 | -61.86 | -72.15 | -- | -- | -- | -795.80 | -- | -516.52 | 0.00 | -- | -- | -- | 44.15 | -- | -- | -- |
| Champions Oncology Inc | 49.22m | -9.73m | 69.74m | 230.00 | -- | -- | -- | 1.42 | -0.7183 | -0.7183 | 3.64 | -0.1514 | 1.56 | -- | 6.17 | 214,017.40 | -30.91 | -5.40 | -96.45 | -11.88 | 40.09 | 47.96 | -19.76 | -3.09 | -- | -- | -- | -- | 9.69 | 21.63 | -1,073.54 | -- | 18.50 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Federated Global Investment Management Corp.as of 31 Dec 2023 | 4.80m | 12.91% |
| Kingdon Capital Management LLCas of 31 Dec 2023 | 2.24m | 6.01% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.55m | 4.17% |
| Avidity Partners Management LPas of 31 Dec 2023 | 1.45m | 3.89% |
| Stonepine Capital Management LLCas of 31 Dec 2023 | 1.36m | 3.64% |
| AMH Equity Ltd.as of 31 Dec 2023 | 550.40k | 1.48% |
| D.A. Davidson & Co. (Investment Management)as of 31 Dec 2023 | 526.49k | 1.42% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 427.58k | 1.15% |
| Acadian Asset Management LLCas of 31 Dec 2023 | 399.38k | 1.07% |
| Geode Capital Management LLCas of 31 Dec 2023 | 355.91k | 0.96% |
